Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or
Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related
psychoses.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University Hospital, Aker
Collaborators:
AstraZeneca Diakonhjemmet Hospital Johanne and Einar Eilertsen's research fund Josef and Haldis Andresen's legacy Laxdale Ltd Norwegian University of Science and Technology Scandinavian Society for Psychopharmacology Shipowner Emil Stray's legacy Solveig and Johan P. Sommer's foundation Stanley Medical Research Institute University of Oslo